株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオマーカーの世界市場 〜2021年:製品・タイプ (安全性・効能・検証)・適応症 (癌・心血管疾患)・用途別

Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery & Development, Disease-Risk) - Global Forecast to 2021

発行 MarketsandMarkets 商品コード 230633
出版日 ページ情報 英文 160 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.82円で換算しております。
Back to Top
バイオマーカーの世界市場 〜2021年:製品・タイプ (安全性・効能・検証)・適応症 (癌・心血管疾患)・用途別 Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery & Development, Disease-Risk) - Global Forecast to 2021
出版日: 2017年02月17日 ページ情報: 英文 160 Pages
概要

世界のバイオマーカー市場は、2016年には279億5000万米ドル、2021年には533億4000万米ドルと、13.8%のCAGR (複合年間成長率) で拡大する見込みです。市場成長の主な要因として、バイオマーカーの活用分野の拡大や、製薬/バイオテクノロジー企業からのR&D資金提供、途上国でのCROの増加と低コストでの治験体制、癌患者数の増加などが挙げられます。特にアジア諸国では、慢性疾患の患者増加やR&D活動の受託などを受けて、大幅な市場成長が見込まれています。

当レポートでは、世界のバイオマーカー市場について調査し、製品および市場の概要、産業構造とバリューチェーン、市場成長への各種影響因子および市場機会の分析、製品形態・バイオマーカーのタイプ・用途・適応症別の市場分析および市場成長予測、地域および主要国の動向、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場のダイナミクス
    • 促進要因
      • バイオマーカーの診断目的での利用増加
        • 個別化医療
        • コンパニオン診断
      • 製薬企業/バイオテクノロジー企業の研究開発 (R&D) 資金の増額
      • 発展途上国におけるCRO (開発業務受託機関) の増加と、低コストでの治験
      • 癌有病者数の増加
      • バイオマーカーの研究に向けた新たな取り組み
    • 抑制要因
      • 資本投資額の高さとコスト収益率の低さ
      • 適切さに欠ける規制・医療費償還制度
      • 試料採取・貯蔵に関する技術的課題
    • 市場機会
      • 新興国市場
    • 課題
      • バイオマーカーを使った検査の臨床有効性の実証

第6章 バイオマーカー市場:製品別

  • イントロダクション
  • 消耗品
  • サービス
  • ソフトウェア

第7章 バイオマーカー市場:タイプ別

  • イントロダクション
  • 安全性バイオマーカー
  • 効能バイオマーカー
    • 予測バイオマーカー
    • 代替バイオマーカー (サロゲートバイオマーカー)
    • 薬力学バイオマーカー
    • 予後バイオマーカー
  • 検証バイオマーカー

第8章 バイオマーカー市場:用途別

  • イントロダクション
  • 診断
  • 創薬・新薬開発
  • 個別化医療
  • 疾患リスク評価
  • その他

第9章 バイオマーカー市場:適応症別

  • イントロダクション
  • 心臓血管疾患
  • 神経疾患
  • 免疫性疾患
  • その他

第10章 バイオマーカー市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
  • アジア
    • 中国
    • 日本
    • その他
  • 他の国々 (RoW)

第11章 競合環境

  • 概要
    • 新製品の発売
    • 事業協力/提携、協定
    • 企業買収
    • その他の動き
  • バイオマーカー市場の代表的企業

第12章 企業プロファイル

  • QIAGEN N.V.
  • PERKINELMER, INC.
  • MERCK MILLIPORE
  • BIO-RAD LABORATORIES, INC.
  • ENZO BIOCHEM, INC.
  • EKF DIAGNOSTICS HOLDINGS, INC.
  • MESO SCALE DIAGNOSTICS, LLC.
  • BIOSIMS TECHNOLOGIES SAS
  • CISBIO BIOASSAYS
  • SIGNOSIS, INC.

第13章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 2120

The global biomarkers market is estimated to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021.

Increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for biomarker research are the major factors driving the growth of the global biomarkers market. In recent years, the Asian biomarkers market has witnessed significant growth due to the increasing use of biomarkers for diagnostic purposes, increasing incidence of chronic diseases, and increasing outsourcing of pharmaceutical R&D activities to outsourcing partners in Asia.

In this report, the global biomarkers market is segmented on the basis of product, type, application, disease indication, and region. On the basis of product, the biomarkers market is segmented into consumables, services, and software. The consumables segment is estimated to account for the largest share of the global biomarkers market in 2016. The large share can primarily be attributed to the lower price of consumables than that of screening and automation instruments.

On the basis of type, the biomarkers market is segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. The efficacy biomarkers segment if further segmented into predictive biomarkers, surrogate biomarkers, pharmacodynamic biomarkers, and prognostic biomarkers. The safety biomarkers segment is estimated to account for the largest share in 2016. This is due to their widespread applications in drug discovery and development.

On the basis of application, the biomarkers market is categorized into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications (DNA fingerprinting, ecotoxicology, and forensics). The diagnostics segment is estimated to account for the largest share of the market in 2016. Factors such as increasing prevalence of cancer, technologically developed biomarker products, individualized treatments for cancer, and the need for early-stage cancer diagnosis are driving the growth of this segment in the biomarkers market.

On the basis of disease indication, the biomarkers market is categorized into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others (renal disorders, urinal diseases, diabetes, and tuberculosis). The cancer segment is estimated to account for the largest share of the biomarkers market in 2016. This is primarily attributed to the increasing prevalence of cancer. The use of cancer biomarkers provides great opportunities for improving the management of cancer patients by enhancing detection and efficacy of treatment.

New product launches was the dominant strategy adopted by key industry participants to increase their market share and cater to unmet needs.

Research Coverage:

From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats), winning imperatives, and burning issues. The report also offers market sizes and data on the growth of various segments in the industry. It focuses on emerging and high-growth segments, high-growth regions, and initiatives of governments. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysis-industry analysis (industry trends) and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments of the biomarkers market; high-growth regions; and market drivers, restraints, and opportunities.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on products offered by the top players in the biomarkers market
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the biomarkers market
  • Market Development: Comprehensive information about lucrative emerging markets-the report analyzes the markets for biomarker products across various regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the biomarkers market
  • Competitive Assessment: In-depth assessment of market ranking, strategies, products, and manufacturing capabilities of the leading players in the biomarkers market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED IN THE REPORT
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
    • 2.2.2. KEY DATA FROM PRIMARY SOURCES
  • 2.3. MARKET RANK ESTIMATION
  • 2.4. KEY INDUSTRY INSIGHTS
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. BIOMARKERS: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: BIOMARKERS MARKET, BY PRODUCT (2016)
  • 4.3. BIOMARKERS MARKET, BY TYPE, 2016 VS. 2021
  • 4.4. BIOMARKERS MARKET SIZE, BY APPLICATION, 2016 VS. 2021
  • 4.5. BIOMARKERS MARKET, BY DISEASE INDICATION, 2016 VS. 2021
  • 4.6. BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.7. LIFE CYCLE ANALYSIS, BY REGION, 2016

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing diagnostic applications of biomarkers
        • 5.2.1.1.1. Personalized medicine
        • 5.2.1.1.2. Companion diagnostics
      • 5.2.1.2. Increasing R&D funding for pharma and biotech companies
      • 5.2.1.3. Increasing number of CROs and low cost of clinical trials in developing countries
      • 5.2.1.4. High prevalence of cancer
      • 5.2.1.5. New initiatives for biomarker research
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High capital investments and low cost-benefit ratio
      • 5.2.2.2. Poorly suited regulatory and reimbursement systems
      • 5.2.2.3. Technical issues related to sample collection and storage
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Emerging economies
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Proving the clinical validity in biomarker-based tests

6. BIOMARKERS MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. CONSUMABLES
  • 6.3. SERVICES
  • 6.4. SOFTWARE

7. BIOMARKERS MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. SAFETY BIOMARKERS
  • 7.3. EFFICACY BIOMARKERS
    • 7.3.1. PREDICTIVE BIOMARKERS
    • 7.3.2. SURROGATE BIOMARKERS
    • 7.3.3. PHARMACODYNAMIC BIOMARKERS
    • 7.3.4. PROGNOSTIC BIOMARKERS
  • 7.4. VALIDATION BIOMARKERS

8. BIOMARKERS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. DIAGNOSTICS
  • 8.3. DRUG DISCOVERY AND DEVELOPMENT
  • 8.4. PERSONALIZED MEDICINE
  • 8.5. DISEASE RISK ASSESSMENT
  • 8.6. OTHER APPLICATIONS

9. BIOMARKERS MARKET, BY DISEASE INDICATION

  • 9.1. INTRODUCTION
  • 9.2. CANCER
  • 9.3. CARDIOVASCULAR DISORDERS
  • 9.4. NEUROLOGICAL DISORDERS
  • 9.5. IMMUNOLOGICAL DISORDERS
  • 9.6. OTHER DISEASES

10. BIOMARKERS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
  • 10.4. ASIA
    • 10.4.1. CHINA
    • 10.4.2. JAPAN
    • 10.4.3. REST OF ASIA
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. COMPETITIVE SITUATION AND TRENDS
    • 11.2.1. PRODUCT LAUNCHES
    • 11.2.2. COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS
    • 11.2.3. ACQUISITIONS
    • 11.2.4. OTHER DEVELOPMENTS
  • 11.3. LEADING PLAYERS IN THE BIOMARKERS MARKET

12. COMPANY PROFILES (Overview, Products and Services, Financials, Strategy & Development)*

  • 12.1. QIAGEN N.V.
  • 12.2. PERKINELMER, INC.
  • 12.3. MERCK MILLIPORE
  • 12.4. BIO-RAD LABORATORIES, INC.
  • 12.5. ENZO BIOCHEM, INC.
  • 12.6. EKF DIAGNOSTICS HOLDINGS, INC.
  • 12.7. MESO SCALE DIAGNOSTICS, LLC.
  • 12.8. BIOSIMS TECHNOLOGIES SAS
  • 12.9. CISBIO BIOASSAYS
  • 12.10. SIGNOSIS, INC.

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. OTHER DEVELOPMENTS
  • 13.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.6. AVAILABLE CUSTOMIZATIONS
  • 13.7. RELATED REPORTS
  • 13.8. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
  • TABLE 2: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 3: BIOMARKER CONSUMABLES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 4: NORTH AMERICA: BIOMARKER CONSUMABLES MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 5: ASIA: BIOMARKER CONSUMABLES MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 6: BIOMARKER SERVICES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 7: NORTH AMERICA: BIOMARKER SERVICES MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 8: ASIA: BIOMARKER SERVICES MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 9: BIOMARKER SOFTWARE MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 10: NORTH AMERICA: BIOMARKER SOFTWARE MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 11: ASIA: BIOMARKER SOFTWARE MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 12: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 13: SAFETY BIOMARKERS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 14: NORTH AMERICA: SAFETY BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 15: ASIA: SAFETY BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 16: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 17: EFFICACY BIOMARKERS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 18: NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 19: ASIA: EFFICACY BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 20: PREDICTIVE BIOMARKERS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 21: NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 22: SURROGATE BIOMARKERS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 23: NORTH AMERICA: SURROGATE BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 24: PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 25: NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 26: PROGNOSTIC BIOMARKERS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 27: NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 28: VALIDATION BIOMARKERS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 29: NORTH AMERICA: VALIDATION BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 30: ASIA: VALIDATION BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 31: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 32: BIOMARKERS MARKET SIZE FOR DIAGNOSTICS DEVELOPMENT, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 33: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR DIAGNOSTICS DEVELOPMENT, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 34: ASIA: BIOMARKERS MARKET SIZE FOR DIAGNOSTICS DEVELOPMENT, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 35: BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 36: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 37: ASIA: BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 38: BIOMARKERS MARKET SIZE FOR PERSONALIZED MEDICINE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 39: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR PERSONALIZED MEDICINE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 40: ASIA: BIOMARKERS MARKET SIZE FOR PERSONALIZED MEDICINE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 41: BIOMARKERS MARKET SIZE FOR DISEASE RISK ASSESSMENT, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 42: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 43: ASIA: BIOMARKERS MARKET SIZE FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 44: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 45: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 46: ASIA: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 47: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 48: KEY CANCER BIOMARKERS IN CLINICAL USE
  • TABLE 49: BIOMARKERS MARKET SIZE FOR CANCER, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 50: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CANCER, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 51: ASIA: BIOMARKERS MARKET SIZE FOR CANCER, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 52: BIOMARKERS FOR CARDIOVASCULAR DISORDER
  • TABLE 53: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 54: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 55: ASIA: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION/COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 56: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 57: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 58: ASIA: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION/COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 59: BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
  • TABLE 60: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 61: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 62: ASIA: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION/COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 63: BIOMARKERS FOR RENAL DISORDERS
  • TABLE 64: BIOMARKERS MARKET SIZE FOR OTHER DISEASES, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 65: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER DISEASES, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 66: ASIA: BIOMARKERS MARKET SIZE FOR OTHER DISEASES, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 67: BIOMARKERS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 68: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 69: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 70: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 71: NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 72: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 73: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 74: U.S.: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 75: U.S.: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 76: U.S.: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 77: U.S.: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 78: U.S.: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 79: CANADA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 80: CANADA: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 81: CANADA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 82: CANADA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 83: CANADA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 84: EUROPE: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 85: EUROPE: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 86: EUROPE: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 87: EUROPE: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 88: EUROPE: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 89: ASIA: BIOMARKERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 90: ASIA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 91: ASIA: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 92: ASIA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 93: ASIA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 94: ASIA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 95: CHINA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 96: CHINA: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 97: CHINA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 98: CHINA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 99: JAPAN: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 100: JAPAN: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 101: JAPAN: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 102: JAPAN: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 103: REST OF ASIA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 104: REST OF ASIA: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 105: REST OF ASIA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 106: REST OF ASIA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 107: ROW: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 108: ROW: BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 109: ROW: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 110: ROW: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 111: ROW: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD BILLION)
  • TABLE 112: BATTLE FOR MARKET SHARE: PRODUCT LAUNCH WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS IN BIOMARKERS MARKET BETWEEN 2014 AND 2016
  • TABLE 113: PRODUCT LAUNCHES, 2014-2016
  • TABLE 114: COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS, 2014-2016
  • TABLE 115: ACQUISITIONS, 2014-2016
  • TABLE 116: OTHER DEVELOPMENTS, 2014-2016
  • TABLE 117: RANK OF COMPANIES IN THE BIOMARKERS MARKET, 2016

LIST OF FIGURES

  • FIGURE 1: BIOMARKERS MARKET SEGMENTATION
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: BIOMARKERS MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD BILLION)
  • FIGURE 8: BIOMARKERS MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD BILLION)
  • FIGURE 9: BIOMARKERS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD BILLION)
  • FIGURE 10: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2016 VS. 2021 (USD BILLION)
  • FIGURE 11: BIOMARKERS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD BILLION)
  • FIGURE 12: BIOMARKERS MARKET TO REGISTER A HIGH, DOUBLE-DIGIT GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 13: CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 14: SAFETY BIOMARKERS WILL CONTINUE TO DOMINATE THE BIOMARKERS MARKET IN 2021
  • FIGURE 15: DIAGNOSTICS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 16: CANCER SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 17: ASIA TO ACCOUNT FOR THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 18: ASIAN MARKET SHOWS LUCRATIVE GROWTH OPPORTUNITIES
  • FIGURE 19: BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 20: INCREASING R&D INVESTMENTS BOOSTING GROWTH IN THE BIOMARKERS MARKET
  • FIGURE 21: INCREASING NUMBER OF NEW CANCER CASES WORLDWIDE (2012 VS. 2015 VS. 2020)
  • FIGURE 22: CONSUMABLES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2016
  • FIGURE 23: SAFETY BIOMARKERS SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 24: DIAGNOSTICS APPLICATION SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2016
  • FIGURE 25: CANCER TO FORM THE LARGEST SEGMENT IN THE BIOMARKERS MARKET IN 2016
  • FIGURE 26: BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 27: ASIA: AN ATTRACTIVE DESTINATION FOR ALL APPLICATION CATEGORIES
  • FIGURE 28: NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 29: ASIA: MARKET SNAPSHOT
  • FIGURE 30: PRODUCT LAUNCH, THE MOST ADOPTED GROWTH STRATEGY FROM 2014 TO 2016
  • FIGURE 31: GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS (2015)
  • FIGURE 32: COMPANY SNAPSHOT: QIAGEN N.V. (2015)
  • FIGURE 33: COMPANY SNAPSHOT: PERKINELMER, INC. (2015)
  • FIGURE 34: COMPANY SNAPSHOT: MERCK MILLIPORE (2015)
  • FIGURE 35: COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2015)
  • FIGURE 36: COMPANY SNAPSHOT: ENZO BIOCHEM, INC. (2016)
  • FIGURE 37: COMPANY SNAPSHOT: EKF DIAGNOSTICS HOLDINGS, INC. (2015)
Back to Top